Deerfield Management Company, L.P. (Series C) Repligen Corp Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Repligen Corp stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,418 shares of RGEN stock, worth $174,995. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,418
Previous 3,362
57.82%
Holding current value
$174,995
Previous $423,000
50.12%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding RGEN
# of Institutions
486Shares Held
54.3MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$934 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$789 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$623 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$200 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$175 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.85B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....